Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts

Acta Oto-Laryngologica

Volumn 128, Issue 8, 2008, Pages 936-940

  Nakagawa, Takahiro ^a   Otsuki, Naoki ^a   Masai, Yohko ^a   Sasaki, Ryohei ^a   Tsukuda, Mamoru ^b   Nibu, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; DNA array; Hypopharyngeal cancer; Radiation; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; ENT1 GENE; FGF GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; MOUSE; NONHUMAN; POLD GENE; PRIORITY JOURNAL; TOP2A GENE; TP GENE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MICE; MICE, NUDE; OXONIC ACID; TEGAFUR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 46849105257     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480701784999     Document Type: Article

References (13)

1. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004;22:2214-32.
2. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005;93:884-9.
3. Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 2006;26(3B):2265-8.
4. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
5. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-23.
6. Lawrence TS, Davis MA, Loney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996;56:3203-6.
7. Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K. A replication-selective adenoviral vector for head and neck cancers. Arch Otolaryngol Head Neck Surg 2005;131:630-4.
8. Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P, et al. Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res 2004;32:e74.
9. Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B, et al. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 2006;8:38-45.
10. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
11. Ijuin T, Nibu K, Doi K, Inoue H, Saitoh M, Ohtsuki N, et al. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer. Acta Otolaryngol (Stockh) 2007;127:305-11.
12. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005;11:7683-91.
13. Takahashi Y, Moriwaki S, Sugiyama Y, Endo Y, Yamazaki K, Mori T, et al. Decreased gene expression responsible for post-ultraviolet DNA repair synthesis in aging: a possible mechanism of age-related reduction in DNA repair capacity. J Invest Dermatol 2005;124:435-42.